Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: preliminary findings from an open trial

P J Reading; A K Luce; I G McKeith

doi:10.1002/mds.1204

Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: preliminary findings from an open trial

Mov Disord. 2001 Nov;16(6):1171-4. doi: 10.1002/mds.1204.

Authors

P J Reading¹, A K Luce, I G McKeith

Affiliation

¹ Department of Neurology, Regional Neurosciences Centre, Newcastle General Hospital, Newcastle upon Tyne, United Kingdom.

PMID: 11748755
DOI: 10.1002/mds.1204

Abstract

This open study assessed the ability of rivastigmine to treat the neuropsychiatric complications of advanced Parkinson's disease. In a group of 12 patients, hallucinations, sleep disturbance, and carer distress were all improved and cognitive performance significantly enhanced by the drug.

Publication types

Clinical Trial
Research Support, Non-U.S. Gov't

MeSH terms

Aged
Carbamates / therapeutic use*
Caregivers / psychology
Cognition Disorders / drug therapy*
Cognition Disorders / etiology
Female
Follow-Up Studies
Hallucinations / drug therapy
Humans
Male
Middle Aged
Neuroprotective Agents / therapeutic use*
Parkinson Disease / psychology*
Phenylcarbamates*
Psychotic Disorders / drug therapy*
Psychotic Disorders / etiology
Rivastigmine
Stress, Psychological
Treatment Outcome

Substances

Carbamates
Neuroprotective Agents
Phenylcarbamates
Rivastigmine